Antihypertensive therapy in patients with paroxysmal form of atrial fibrillation: is drug selection important?


Cite item

Full Text

Abstract

The study included 84 patients with paroxysmal atrial fibrillation (AF) and hypertension of different degrees. We evaluate the influence of antihypertensive therapy by calcium antagonists (CA) and inhibitors of angiotensin-converting enzyme (ACE) on the clinical course of paroxysmal AF in patients with hypertension and structural and functional remodeling of the myocardium. It was shown that the efficiency of blood pressure (BP) lowering by CA and ACE inhibitors is similar. BP control leads to significant decreasing of the frequency of AF paroxysm compared this using only classic ant arrhythmic drug. ACE inhibitors characterized by stable anti-relapsing activity, but protective effect CA decreased on 7,9% after 12 months. Compared with CA therapy by ACE inhibitors led to decreasing of structural and functional remodeling of the myocardium and reduction of AF paroxysm frequency on 61,5%, what can be caused by specific blockage of renin-angiotensin-aldosterone system.

References

  1. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-19.
  2. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
  3. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84.
  4. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005;36:1115-19.
  5. Verdecchia P, Reboldi R, Bentivoglio M, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003;41:218-23.
  6. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertensionthe Captopril Prevention Project (CAPP) randomised trial. Lancet 1999;353:611-16.
  7. Sarubbi B, Ducceschi V, Santangelo L, et al. Arrhythmias in patients with mechanical ventricular dysfunction and myocardial stretch: role of mechano-electric feedback. Can J Cardiol 1998;14(2):245-52.
  8. Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. Am Col. Cardiol 2001;37(4):1042-48.
  9. Goette A, Staack T, Röcken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-77.
  10. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of atrial fibrillation substrate in dogs with ventricular tachycardia-induced congestive heart failure. Circulation 2001;104:2608-14.
  11. Goette A, Lendeckel U, Klein HU. Signal transduction systems and atrial fibrillation. Cardiovasc Res 2002;54:247-58.
  12. Tsang TS, Barnes ME, Bailey KR, et al. Left atrial volumeimportant risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc 2001;76:467-75.
  13. Vaziri SM, Larson MG, Benjamin EJ, et al. Echocardiographic predictors of nonrheumatic atrial fibrillation the Framingham Heart Study. Circulation 1994;89:724-30.
  14. Kalifa J, Jalife J, Zaitsev AV, et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation Circulation 2003;108:668-71.
  15. Morillo CA, Klein GJ, Jones DL, et al. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995;91:1588-95.
  16. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 1997;96:1686-95.
  17. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in ake chronically instrumented goats. Circulation 1995;92:1954-68.
  18. Shi Y, Ducharme A, Li D, et al. Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res 2001;52:217-25.
  19. Li D, Fareh S, Leung TK, et al. Promotion of atrial fibrillation by heart failure in dogsatrial remodeling of a different sort. Circulation 1999;100:87-95.
  20. Shi Y, Tardif J-C, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002;54:456-61.
  21. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-17.
  22. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2342&mid=1085056570&magid=175&full=1

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media